Raymond James Trust N. A. decreased its holdings in shares of  Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 3.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 129,260 shares of the biopharmaceutical company’s stock after selling 5,235 shares during the period. Raymond James Trust N.A.’s holdings in Bristol-Myers Squibb were worth $9,301,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of BMY. Dakota Wealth Management bought a new position in shares of  Bristol-Myers Squibb in the first quarter valued at approximately $332,000.  Covestor Ltd raised its stake in shares of  Bristol-Myers Squibb by 111.5% in the first quarter. Covestor Ltd now owns 2,052 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 1,082 shares during the last quarter.  NewEdge Advisors LLC raised its stake in shares of  Bristol-Myers Squibb by 53.2% in the first quarter. NewEdge Advisors LLC now owns 165,336 shares of the biopharmaceutical company’s stock valued at $12,075,000 after acquiring an additional 57,444 shares during the last quarter.  Ergoteles LLC bought a new position in shares of  Bristol-Myers Squibb in the first quarter valued at approximately $1,997,000.  Finally, Mackenzie Financial Corp raised its stake in shares of  Bristol-Myers Squibb by 25.1% in the first quarter. Mackenzie Financial Corp now owns 338,563 shares of the biopharmaceutical company’s stock valued at $24,725,000 after acquiring an additional 68,018 shares during the last quarter. Institutional investors own  75.51% of the company’s stock.

Shares of BMY stock opened at $69.88 on Wednesday. Bristol-Myers Squibb has a 12-month low of $65.28 and a 12-month high of $81.43. The firm has a market capitalization of $146.98 billion, a price-to-earnings ratio of 23.81, a price-to-earnings-growth ratio of 1.55 and a beta of 0.45. The company has a quick ratio of 1.14, a current ratio of 1.25 and a debt-to-equity ratio of 1.13. The firm has a fifty day moving average of $69.47 and a 200-day moving average of $72.78.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last announced its quarterly earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.71 by $0.11. Bristol-Myers Squibb had a net margin of 13.71% and a return on equity of 51.60%. The company had revenue of $11.41 billion during the quarter, compared to analyst estimates of $11.20 billion. During the same quarter in the previous year, the business earned $1.83 EPS. The firm’s revenue was down 4.8% on a year-over-year basis.  On average, equities research analysts forecast that  Bristol-Myers Squibb will post 7.98 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, May 1st. Stockholders of record on Monday, April 10th will be issued a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 3.26%. The ex-dividend date of this dividend is Thursday, April 6th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 77.29%.

In related news, EVP Ann Powell sold 11,183 shares of the business’s stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.69, for a total value of $835,258.27. Following the sale, the executive vice president now directly owns 23,043 shares of the company’s stock, valued at approximately $1,721,081.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Ann Powell sold 11,183 shares of the business’s stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.69, for a total value of $835,258.27. Following the sale, the executive vice president now directly owns 23,043 shares of the company’s stock, valued at approximately $1,721,081.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Giovanni Caforio sold 240,000 shares of the business’s stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.65, for a total transaction of $17,916,000.00. Following the completion of the sale, the chief executive officer now directly owns 236,104 shares in the company, valued at $17,625,163.60. The disclosure for this sale can be found here. 0.08% of the stock is owned by company insiders.

BMY has been the subject of a number of research reports. Jefferies Financial Group initiated coverage on shares of Bristol-Myers Squibb in a report on Monday, March 6th. They issued a “hold” rating and a $62.00 price target for the company. Cantor Fitzgerald initiated coverage on shares of Bristol-Myers Squibb in a report on Tuesday, January 17th. They issued an “overweight” rating and a $95.00 price target for the company. Atlantic Securities raised their price target on shares of Bristol-Myers Squibb from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, February 3rd. StockNews.com initiated coverage on shares of Bristol-Myers Squibb in a report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Finally, Morgan Stanley raised their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “underweight” rating in a report on Friday, February 3rd. One equities research analyst  has rated the stock with a sell rating, seven have issued  a hold rating, seven have given a buy rating and one  has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $79.69.

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.